Evoq Remedies Ltd. (BSE: EVOQ.BO) Stock Competitors & Peer Comparison

Evoq Remedies Ltd. (BSE: EVOQ.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOQ.BO stands at 42.6M. In comparison, ENTERO.NS has a market cap of 62B. Regarding current trading prices, EVOQ.BO is priced at ₹1.71 on the BSE, while ENTERO.NS trades at ₹1,423.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOQ.BO currently has a P/E ratio of -17.10, whereas ENTERO.NS's P/E ratio is 46.91. In terms of profitability, EVOQ.BO's ROE is -0.01%, compared to ENTERO.NS's ROE of +0.07%. Regarding short-term risk, EVOQ.BO is less volatile compared to ENTERO.NS. This indicates lower risk in terms of short-term price fluctuations for EVOQ.BO.Check ENTERO.NS's competition here

Evoq Remedies Ltd. (BSE: EVOQ.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOQ.BO stands at 42.6M. In comparison, EVERESTO.BO has a market cap of 2.9B. Regarding current trading prices, EVOQ.BO is priced at ₹1.71 on the BSE, while EVERESTO.BO trades at ₹297.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOQ.BO currently has a P/E ratio of -17.10, whereas EVERESTO.BO's P/E ratio is 52.25. In terms of profitability, EVOQ.BO's ROE is -0.01%, compared to EVERESTO.BO's ROE of +0.07%. Regarding short-term risk, EVOQ.BO is less volatile compared to EVERESTO.BO. This indicates lower risk in terms of short-term price fluctuations for EVOQ.BO.Check EVERESTO.BO's competition here

Evoq Remedies Ltd. (BSE: EVOQ.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOQ.BO stands at 42.6M. In comparison, QMSMEDI.NS has a market cap of 2.9B. Regarding current trading prices, EVOQ.BO is priced at ₹1.71 on the BSE, while QMSMEDI.NS trades at ₹148.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOQ.BO currently has a P/E ratio of -17.10, whereas QMSMEDI.NS's P/E ratio is 21.23. In terms of profitability, EVOQ.BO's ROE is -0.01%, compared to QMSMEDI.NS's ROE of N/A. Regarding short-term risk, EVOQ.BO is less volatile compared to QMSMEDI.NS. This indicates lower risk in terms of short-term price fluctuations for EVOQ.BO.Check QMSMEDI.NS's competition here

Evoq Remedies Ltd. (BSE: EVOQ.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOQ.BO stands at 42.6M. In comparison, ACHYUT.BO has a market cap of 1.7B. Regarding current trading prices, EVOQ.BO is priced at ₹1.71 on the BSE, while ACHYUT.BO trades at ₹7.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOQ.BO currently has a P/E ratio of -17.10, whereas ACHYUT.BO's P/E ratio is 700.00. In terms of profitability, EVOQ.BO's ROE is -0.01%, compared to ACHYUT.BO's ROE of +0.01%. Regarding short-term risk, EVOQ.BO is less volatile compared to ACHYUT.BO. This indicates lower risk in terms of short-term price fluctuations for EVOQ.BO.Check ACHYUT.BO's competition here

Evoq Remedies Ltd. (BSE: EVOQ.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOQ.BO stands at 42.6M. In comparison, RAMAVISION.BO has a market cap of 1.7B. Regarding current trading prices, EVOQ.BO is priced at ₹1.71 on the BSE, while RAMAVISION.BO trades at ₹161.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOQ.BO currently has a P/E ratio of -17.10, whereas RAMAVISION.BO's P/E ratio is 166.32. In terms of profitability, EVOQ.BO's ROE is -0.01%, compared to RAMAVISION.BO's ROE of +0.21%. Regarding short-term risk, EVOQ.BO is less volatile compared to RAMAVISION.BO. This indicates lower risk in terms of short-term price fluctuations for EVOQ.BO.Check RAMAVISION.BO's competition here

Evoq Remedies Ltd. (BSE: EVOQ.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOQ.BO stands at 42.6M. In comparison, BALAXI.NS has a market cap of 1.2B. Regarding current trading prices, EVOQ.BO is priced at ₹1.71 on the BSE, while BALAXI.NS trades at ₹22.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOQ.BO currently has a P/E ratio of -17.10, whereas BALAXI.NS's P/E ratio is -4.23. In terms of profitability, EVOQ.BO's ROE is -0.01%, compared to BALAXI.NS's ROE of +0.01%. Regarding short-term risk, EVOQ.BO is less volatile compared to BALAXI.NS. This indicates lower risk in terms of short-term price fluctuations for EVOQ.BO.Check BALAXI.NS's competition here

Evoq Remedies Ltd. (BSE: EVOQ.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOQ.BO stands at 42.6M. In comparison, BIJHANS.BO has a market cap of 642.2M. Regarding current trading prices, EVOQ.BO is priced at ₹1.71 on the BSE, while BIJHANS.BO trades at ₹85.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOQ.BO currently has a P/E ratio of -17.10, whereas BIJHANS.BO's P/E ratio is 570.80. In terms of profitability, EVOQ.BO's ROE is -0.01%, compared to BIJHANS.BO's ROE of N/A. Regarding short-term risk, EVOQ.BO is similarly volatile compared to BIJHANS.BO. This indicates similar risk in terms of short-term price fluctuations for EVOQ.BO.Check BIJHANS.BO's competition here

Evoq Remedies Ltd. (BSE: EVOQ.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOQ.BO stands at 42.6M. In comparison, VIVOBIOT.BO has a market cap of 428.5M. Regarding current trading prices, EVOQ.BO is priced at ₹1.71 on the BSE, while VIVOBIOT.BO trades at ₹19.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOQ.BO currently has a P/E ratio of -17.10, whereas VIVOBIOT.BO's P/E ratio is -23.55. In terms of profitability, EVOQ.BO's ROE is -0.01%, compared to VIVOBIOT.BO's ROE of -0.03%. Regarding short-term risk, EVOQ.BO is less volatile compared to VIVOBIOT.BO. This indicates lower risk in terms of short-term price fluctuations for EVOQ.BO.Check VIVOBIOT.BO's competition here

Evoq Remedies Ltd. (BSE: EVOQ.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOQ.BO stands at 42.6M. In comparison, RAJNISH.BO has a market cap of 396M. Regarding current trading prices, EVOQ.BO is priced at ₹1.71 on the BSE, while RAJNISH.BO trades at ₹0.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOQ.BO currently has a P/E ratio of -17.10, whereas RAJNISH.BO's P/E ratio is -6.50. In terms of profitability, EVOQ.BO's ROE is -0.01%, compared to RAJNISH.BO's ROE of -0.05%. Regarding short-term risk, EVOQ.BO is less volatile compared to RAJNISH.BO. This indicates lower risk in terms of short-term price fluctuations for EVOQ.BO.Check RAJNISH.BO's competition here

Evoq Remedies Ltd. (BSE: EVOQ.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOQ.BO stands at 42.6M. In comparison, CBPL.BO has a market cap of 376.5M. Regarding current trading prices, EVOQ.BO is priced at ₹1.71 on the BSE, while CBPL.BO trades at ₹49.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOQ.BO currently has a P/E ratio of -17.10, whereas CBPL.BO's P/E ratio is 12.35. In terms of profitability, EVOQ.BO's ROE is -0.01%, compared to CBPL.BO's ROE of +0.10%. Regarding short-term risk, EVOQ.BO is less volatile compared to CBPL.BO. This indicates lower risk in terms of short-term price fluctuations for EVOQ.BO.Check CBPL.BO's competition here

Evoq Remedies Ltd. (BSE: EVOQ.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOQ.BO stands at 42.6M. In comparison, MONOPHARMA.NS has a market cap of 149.3M. Regarding current trading prices, EVOQ.BO is priced at ₹1.71 on the BSE, while MONOPHARMA.NS trades at ₹8.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOQ.BO currently has a P/E ratio of -17.10, whereas MONOPHARMA.NS's P/E ratio is 4.83. In terms of profitability, EVOQ.BO's ROE is -0.01%, compared to MONOPHARMA.NS's ROE of N/A. Regarding short-term risk, EVOQ.BO is less volatile compared to MONOPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for EVOQ.BO.Check MONOPHARMA.NS's competition here

Evoq Remedies Ltd. (BSE: EVOQ.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOQ.BO stands at 42.6M. In comparison, NEXUSSURGL.BO has a market cap of 106.6M. Regarding current trading prices, EVOQ.BO is priced at ₹1.71 on the BSE, while NEXUSSURGL.BO trades at ₹19.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOQ.BO currently has a P/E ratio of -17.10, whereas NEXUSSURGL.BO's P/E ratio is 228.86. In terms of profitability, EVOQ.BO's ROE is -0.01%, compared to NEXUSSURGL.BO's ROE of +0.56%. Regarding short-term risk, EVOQ.BO is less volatile compared to NEXUSSURGL.BO. This indicates lower risk in terms of short-term price fluctuations for EVOQ.BO.Check NEXUSSURGL.BO's competition here

Evoq Remedies Ltd. (BSE: EVOQ.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVOQ.BO stands at 42.6M. In comparison, NATURO.BO has a market cap of 51.5M. Regarding current trading prices, EVOQ.BO is priced at ₹1.71 on the BSE, while NATURO.BO trades at ₹2.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVOQ.BO currently has a P/E ratio of -17.10, whereas NATURO.BO's P/E ratio is -5.93. In terms of profitability, EVOQ.BO's ROE is -0.01%, compared to NATURO.BO's ROE of -0.02%. Regarding short-term risk, EVOQ.BO is less volatile compared to NATURO.BO. This indicates lower risk in terms of short-term price fluctuations for EVOQ.BO.Check NATURO.BO's competition here